PDE7
inhibitor for
Fragile X syndrome, Angelman
Syndrome and related rare
neurodevelopmental disorders
Why PDE7?
Cyclic AMP signalling pathway relevant to neuronal and synaptic function.
Data room contents
Mechanistic rationale · in vitro pharmacology · selectivity · PK /brain exposure · behavioural efficacy · tolerability · IP position · proposed development plan
Why partner now?
Confidential package available for licensing
PDE7
inhibitors do not cause the emetic effects (nausea and vomiting) that limit other similar drugs
Target | PDE7 |
|---|---|
Modality | Small molecule |
Stage
| Advanced preclinical |
Status | Available |
Lead indication
|
|
